Aimovig®

Active substance

erenumab

Holder

Novartis Pharma

Status

Closed

Indication

Treatment of patients diagnosed with migraine, who are in need of prophylactic treatment and for whom no acceptable alternative prophylactic treatment is available

Public documents

Approbation

Information for the patient

Informed consent

Last update

03/06/2020

Last updated on 17/11/2021